Spinal Cord Stimulation for Neuropathy

Spinal cord stimulation (SCS) is an interventional pain management procedure in which a small device — similar in concept to a cardiac pacemaker — delivers low-level electrical impulses to the spinal cord to interrupt pain signal transmission to the brain. It is used for patients with chronic neuropathic pain who have not achieved adequate relief from conservative treatments including medications, physical therapy, and other interventions. SCS is not a first-line treatment — it is typically considered after other approaches have been tried for at least 6 to 12 months without sufficient relief. However, for appropriately selected patients with refractory diabetic neuropathy, failed back surgery syndrome, complex regional pain syndrome (CRPS), and other painful peripheral neuropathies, SCS can produce substantial and durable pain reduction. All decisions about SCS should be made with a fellowship-trained pain management specialist and neurosurgeon.

How It Works

SCS works through several mechanisms. The traditional understanding — called the gate control theory — proposed that electrical stimulation of large-diameter sensory fibers in the dorsal columns of the spinal cord effectively ‘closes the gate’ to pain signals carried by smaller pain fibers. Modern high-frequency and burst SCS patterns appear to work through additional mechanisms, including modulation of inhibitory interneurons in the dorsal horn and changes in glial cell activity that reduce central sensitization.

The implantable system consists of thin electrodes placed epidurally (in the space just outside the spinal cord’s protective covering) and connected via insulated wires to a pulse generator (IPG) implanted under the skin, typically in the lower back or abdomen. The IPG is programmable — the stimulation parameters (frequency, pulse width, amplitude, and electrode configuration) can be adjusted noninvasively using an external programmer. Modern rechargeable IPGs can last 5 to 10 years before requiring replacement.

The Trial Period

Before permanent implantation, virtually all SCS candidates undergo a trial stimulation period of 5 to 10 days. During the trial, electrodes are placed percutaneously (through the skin) under fluoroscopic guidance and connected to an external trial stimulator — the permanent IPG is not implanted during the trial. The patient goes home with the trial system in place, continuing normal daily activities while assessing the degree of pain relief.

A successful trial is typically defined as at least 50 percent reduction in pain scores compared to baseline, along with functional improvement (better sleep, increased activity tolerance) and patient satisfaction with the stimulation sensation. Trials that meet these criteria are predictive of good long-term outcomes with permanent implantation. Patients who do not respond adequately during the trial are not candidates for permanent implantation — this is the key risk-management step that separates SCS from many other interventions.

Who Is a Candidate?

Appropriate candidates for SCS evaluation typically have: a well-characterized neuropathic pain condition with an established diagnosis, chronic pain lasting at least 6 to 12 months, inadequate response to conventional treatments (medications, physical therapy), no untreated surgical lesion requiring corrective surgery first, no active infections, no serious psychiatric comorbidity that would impair device management or cooperation, and no absolute contraindications (certain cardiac devices, inability to safely undergo the procedure).

Diagnostic criteria and patient selection algorithms continue to evolve. For diabetic neuropathy specifically, evidence supports SCS when pain is refractory to pharmacological management and the patient has a reasonable glycemic control baseline. For CRPS and failed back surgery syndrome, SCS evidence is among the strongest in the interventional pain field. Patients interested in SCS should be referred to a pain management specialist with specific SCS experience — ideally at a program that performs high volumes of these procedures.

Outcomes and Expectations

Multiple randomized controlled trials and systematic reviews have established the efficacy of SCS for several neuropathic pain conditions. For painful diabetic neuropathy, a 2014 RCT by de Vos et al. showed that SCS combined with best medical management produced significantly greater pain reduction and quality-of-life improvement than best medical management alone over 6 months. Meta-analyses of SCS for painful diabetic neuropathy consistently show 50 to 80 percent of implanted patients achieving at least 50% pain reduction.

Long-term effectiveness — maintaining benefit at 3 to 5 years — has been documented in observational studies. Hardware complications (lead migration, infection, device malfunction) occur in approximately 10 to 30% of patients over the device lifetime and may require revision procedures. Advances in rechargeable batteries, wireless programming, and MRI-compatible systems have improved the practical durability and manageability of modern SCS systems. Most patients with successful SCS achieve reduced medication use, better sleep, and improved functional capacity.

Frequently Asked Questions

Is spinal cord stimulation covered by Medicare for neuropathy?

Medicare covers SCS for specific approved indications, including failed back surgery syndrome and CRPS. Coverage for painful diabetic neuropathy has expanded as evidence has strengthened. Prior authorization is required. Commercial insurance coverage varies by plan and payer. A pain management specialist’s office can help with the pre-authorization process and determine your specific coverage before committing to the trial phase.

Does SCS completely eliminate neuropathy pain?

For most patients, SCS reduces but does not eliminate pain. The goal of SCS therapy is typically 50% or greater pain reduction — a threshold associated with meaningful functional improvement and quality-of-life benefit. Complete elimination of pain is less common. Many patients also experience a change in pain quality — from severe burning to a milder, more tolerable sensation — even when intensity reduction is modest.

Can I have an MRI with a spinal cord stimulator implanted?

It depends on the specific device. Some modern SCS systems are MRI-conditional — they can be used in an MRI under specific conditions (certain field strengths, body regions, device settings). Older systems may be MRI-incompatible. Before SCS implantation, discuss your personal MRI history and anticipated future needs with the implanting physician, as MRI compatibility may influence device selection.